Literature DB >> 9044298

Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients.

A Mahiout1, G Ehlerding, R Brunkhorst.   

Abstract

In patients on continuous ambulant peritoneal dialysis (CAPD) treatment, the peritoneal membrane is continuously exposed to the high glucose concentration contained in the dialysate. This may lead to the local generation of advanced glycation end-products (AGEs). To test this hypothesis we evaluated the plasma and dialysate AGE concentrations in five CAPD patients. The dialysate was measured after a 1 h and after a 12 h dwell time. Additionally, in two patients an immunohistochemical investigation of the peritoneal membrane for AGE was performed. For the determination of AGE an ELISA using a polyclonal antibody against AGE bovine serum albumin was used; the immunohistochemical staining was performed using the streptavidin-biotin complex method. We found only low concentrations of AGE in the dialysate after a 1 h dwell time; after 12 h, however, the dialysate AGE was even greater than the plasma concentration. In both peritoneal specimens we found positive staining for AGE in the interstitium of the mesothelial layer. The dialysate AGE contained a high proportion of high-molecular-weight AGE proteins and low-molecular-weight AGE was found to be in the same concentration range as the total serum AGE. We conclude that there is local generation of AGE in the peritoneal membrane and a 'washing out' of AGE from the peritoneal membrane during longer dwell times. We speculate that the accumulation of AGE might lead to some of the functional and morphological alterations observed after long-term CAPD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9044298     DOI: 10.1093/ndt/11.supp5.2

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

Review 1.  Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.

Authors:  Sandeep K Mallipattu; John C He; Jaime Uribarri
Journal:  Semin Dial       Date:  2012-04-30       Impact factor: 3.455

2.  The Effect of Far-Infrared Therapy on the Peritoneal Expression of Glucose Degradation Products in Diabetic Patients on Peritoneal Dialysis.

Authors:  Chia-Ning Chang; Chih-Yuan Niu; Ann Charis Tan; Chia-Hao Chan; Chun-Fan Chen; Tz-Heng Chen; Szu-Yuan Li; Yung-Tai Chen; Fan-Yu Chen; Wen-Sheng Liu; Chih-Ching Lin; Guor-Jien Wei
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

3.  The role of icodextrin in peritoneal dialysis: protocol for a systematic review and meta-analysis.

Authors:  Monika Becker; Stefanie Bühn; Jessica Breuing; Catherine A Firanek; Simone Hess; Hisanori Nariai; Mark R Marshall; James A Sloand; Qiang Yao; Käthe Goossen; Dawid Pieper
Journal:  Syst Rev       Date:  2019-01-30

4.  Degradation and de novo formation of nine major glucose degradation products during storage of peritoneal dialysis fluids.

Authors:  Sabrina Gensberger-Reigl; Ingrid Weigel; Joachim Stützer; Andrea Auditore; Tim Nikolaus; Monika Pischetsrieder
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.